Australia - Inggris - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 28.344 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; croscarmellose sodium; sodium stearylfumarate; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - sitagliptin hydrochloride monohydrate is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg; metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; sodium fumarate; sodium stearyl phthalamate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - sitagliptin/metformin maple (sitagliptin hydrochloride monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate., [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg; metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; sodium fumarate; sodium stearyl phthalamate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - sitagliptin/metformin mylan (sitagliptin hydrochloride monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate., [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 27.25 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: sodium stearylfumarate; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; calcium hydrogen phosphate dihydrate; povidone; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - sitagliptin pcor is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 27.25 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium stearylfumarate; calcium hydrogen phosphate dihydrate; croscarmellose sodium; povidone; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - sitagliptin pcor is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 54.5 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; sodium stearylfumarate; povidone; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin pcor is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Belgia - Inggris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - sitagliptin hydrochloride monohydrate 56,685 mg - eq. sitagliptin 50 mg; metformin hydrochloride 850 mg - film-coated tablet - 50 mg - 850 mg - sitagliptin hydrochloride monohydrate 56.685 mg; metformin hydrochloride 850 mg - metformin and sitagliptin

Belgia - Inggris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - sitagliptin hydrochloride monohydrate 56,685 mg - eq. sitagliptin 50 mg; metformin hydrochloride 1000 mg - film-coated tablet - 50 mg - 1000 mg - sitagliptin hydrochloride monohydrate 56.685 mg; metformin hydrochloride 1000 mg - metformin and sitagliptin

Belgia - Inggris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz gmbh - sitagliptin hydrochloride monohydrate 56,7 mg - eq. sitagliptin 50 mg; metformin hydrochloride 850 mg - film-coated tablet - 50 mg - 850 mg - sitagliptin hydrochloride monohydrate 56.7 mg; metformin hydrochloride 850 mg - metformin and sitagliptin

Belgia - Inggris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz gmbh - sitagliptin hydrochloride monohydrate 56,7 mg - eq. sitagliptin 50 mg; metformin hydrochloride 1000 mg - film-coated tablet - 50 mg - 1000 mg - sitagliptin hydrochloride monohydrate 56.7 mg; metformin hydrochloride 1000 mg - metformin and sitagliptin